Welcome to our dedicated page for Perspective Therapeutics SEC filings (Ticker: CATX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Perspective Therapeutics filings document a clinical-stage radiopharmaceutical oncology business built around Lead-212 targeted therapy, imaging diagnostics, and regional manufacturing capabilities. Form 8-K reports include clinical-program exhibits, corporate presentations, preliminary financial information, and annual results for its VMT-α-NET, VMT01, and PSV359 programs.
The company’s SEC record also covers capital-structure matters, including common stock and pre-funded warrant offerings under a shelf registration statement, as well as material agreements, proxy disclosures on board matters, executive compensation, equity awards, shareholder voting items, governance, and other public-company reporting obligations.
Joel Sendek, serving as Chief Financial Officer and a director of Perspective Therapeutics, Inc. (CATX), filed an initial Form 3 reporting the 09/04/2025 event date. The filing states that the reporting person does not beneficially own any securities of the issuer. The form references Exhibit 24 (Power of Attorney) and was signed via attorney-in-fact on 09/05/2025.
Maria E. Martinez, a director of Perspective Therapeutics, Inc. (CATX), was granted 75,000 stock options on 09/03/2025 with an exercise price of $3.38. The options vest monthly over three years in 36 substantially equal installments beginning one month after the grant date, are exercisable beginning 09/03/2025, and expire on 09/03/2035. After the reported transaction the reporting person beneficially owns 75,000 shares underlying the option on a direct basis. The Form 4 was signed on behalf of Maria E. Martinez by an attorney-in-fact on 09/05/2025.
Perspective Therapeutics, Inc. (CATX) filed a Form 3 reporting Maria E. Martinez as a Director and a reporting person. The event date listed is 09/03/2025. The filing states explicitly that no securities are beneficially owned by the reporting person and references Exhibit 24 (Power of Attorney). The form is signed by Maria E. Martinez via attorney-in-fact on 09/05/2025.
Perspective Therapeutics, Inc. appointed Joel Sendek as its new Chief Financial Officer and principal financial officer, effective September 4, 2025, replacing Juan Graham in the CFO role. The company detailed Mr. Sendek’s background, compensation, equity incentives, and severance protections in his employment agreement.
Mr. Sendek will receive a $500,000 annual base salary, a target annual bonus equal to 40% of base salary, and a one-time option grant to purchase 600,000 shares of common stock, vesting over four years. The agreement also provides 12 months of salary, bonus-related amounts, COBRA premiums, and accelerated vesting of equity awards under certain termination and change-in-control conditions, subject to a release of claims.
Perspective Therapeutics, Inc. reported that its Board of Directors voted to increase the board size from five to six members and appointed Maya Martinez-Davis as a director, effective September 3, 2025. She will also serve on the Compensation Committee and the Nominations and Corporate Governance Committee.
Under the company’s Non-Employee Director Compensation Program, Ms. Martinez-Davis will receive an annual cash retainer of $60,000 and an initial grant of 75,000 stock options, with the grant date fair value capped at $450,000. These options vest in 36 equal monthly installments starting one month after the grant date, contingent on her continued service. The company expects her to enter into its standard indemnification agreement, and it states there are no related-party transactions requiring disclosure. A press release announcing her appointment was issued on September 3, 2025 and furnished as Exhibit 99.1.
Perspective Therapeutics, Inc. filed a current report to note that on September 2, 2025, the company updated its corporate presentation. The updated presentation is included as Exhibit 99.1 and is incorporated by reference into the disclosure. This type of presentation typically provides an overview of the business and strategy for investors, but the specific contents are not detailed here.
Perspective Therapeutics, Inc. is a radiopharmaceutical developer focused on targeted alpha therapies. At June 30, 2025 the company reported $28.85 million in cash and $162.73 million in short-term investments (combined $191.6 million), and management believes these resources will fund current planned operations into late 2026.
Operating spending rose notably year-over-year as R&D increased to $30.95 million for the six months ended June 30, 2025 and total operating expenses were $46.50 million, producing a six-month net loss of $39.66 million. The balance sheet shows total assets of $310.7 million, an accumulated deficit of $271.4 million and 74,262,990 common shares outstanding (per the filing).
Clinical progress reported: opening of Cohort 3 for [212Pb]VMT-α-NET (Cohort 2 had 46 patients treated), FDA "study may proceed" for PSV359 with two patients treated as of July 31, 2025, and Fast Track designation for [212Pb]VMT01. The company also reported recent patent grants and continued investments in manufacturing capacity.
Perspective Therapeutics, Inc. reported that it issued a press release announcing its financial results for the quarter ended June 30, 2025 and furnished that press release as Exhibit 99.1 to this Form 8-K. The filing also states the company posted an updated corporate presentation on its website and furnished that presentation as Exhibit 99.2. The 8-K clarifies that the information is "furnished" and therefore is not deemed "filed" for purposes of Section 18 of the Exchange Act.
The filing text does not include the actual financial figures or metrics; those details are contained in the referenced exhibits. This disclosure informs investors that quarter-end results and investor materials have been released, while the legal notice about furnishing limits incorporation and Section 18 liability.